A5102836594- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Hepatitis C virus research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatitis B Virus Studies
- Viral-associated cancers and disorders
- Cancer, Lipids, and Metabolism
- Alcohol Consumption and Health Effects
- Transplantation: Methods and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Renal Transplantation Outcomes and Treatments
- Hepatitis Viruses Studies and Epidemiology
- Liver Diseases and Immunity
- Inflammatory Biomarkers in Disease Prognosis
- Genetic and Kidney Cyst Diseases
- Cardiovascular Function and Risk Factors
- Cancer Cells and Metastasis
- Pulmonary Hypertension Research and Treatments
- Multiple and Secondary Primary Cancers
- Lymphoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Neutropenia and Cancer Infections
University of California, San Francisco
2016-2025
Hubei University of Medicine
2024-2025
The Affiliated Yongchuan Hospital of Chongqing Medical University
2025
Chongqing Medical University
2025
University of California San Francisco Medical Center
2021
First Affiliated Hospital of Chinese PLA General Hospital
2014
Shanghai Traditional Chinese Medicine Hospital
2014
Fuda Cancer Hospital
2014
Jinan University
2014
Bayer (United States)
2013
The precise staging of hepatocellular carcinoma (HCC) based on the size and number lesions that predict recurrence after orthotopic liver transplantation (OLT) has not been clearly established. We therefore analyzed outcome 70 consecutive patients with cirrhosis HCC who underwent OLT over a 12–year period at our institution. Pathologic tumor explanted was American Tumor Study Group modified Tumor–Node–Metastases (TNM) Staging Classification. occurred in 11.4% OLT. Kaplan–Meier survival rates...
We previously suggested that in patients with heptocellular carcinoma (HCC), the conventional Milan criteria (T1/T2) for orthotopic liver transplantation (OLT) could be modestly expanded based on pathology (UCSF criteria). The present study was undertaken to prospectively validate UCSF pretransplant imaging. Over a 5-year period, were used as selection guidelines OLT 168 patients, including 38 exceeding but meeting (T3A). 1- and recurrence-free probabilities 95.9% 90.9%, respective survivals...
Abstract We previously reported encouraging results of down-staging hepatocellular carcinoma (HCC) to meet conventional T2 criteria (one lesion 2–5 cm or two three lesions <3 cm) for orthotopic liver transplantation (OLT) in 30 patients as a test concept. In this ongoing prospective study, we analyzed longer-term outcome data on HCC larger cohort 61 with tumor stage exceeding who were enrolled between June 2002 and January 2007. Eligibility included: (1) one >5 up 8 cm; (2) at least...
We report on the long-term intention-to-treat (ITT) outcome of 118 patients with hepatocellular carcinoma (HCC) undergoing downstaging to within Milan/United Network for Organ Sharing T2 criteria before liver transplantation (LT) since 2002 and compare results 488 listed LT HCC meeting at listing in same period. The subgroups include 1 lesion >5 ≤8 cm (n = 43), 2 or 3 lesions least one >3 ≤5 total tumor diameter 61), 4-5 each ≤3 14). In group, 64 (54.2%) had received 5 (7.5%) developed...
We previously proposed modified staging criteria for predicting acceptable outcome after orthotopic liver transplantation (OLT) hepatocellular carcinoma (HCC). These were solitary tumor ≤6.5 cm, or three fewer nodules with the largest lesion ≤4.5 cm and total diameter ≤8 without gross vascular invasion (University of California, San Francisco [UCSF] criteria). In this study, we further evaluated performance Milan (solitary ≤5 lesions none >3 cm), UCSF criteria, Pittsburgh...
Hepatocelluar carcinoma (HCC) is the most common primary malignancy of liver in adults and third cause cancer death worldwide. The incidence HCC United States rising steadily because prevalence hepatitis C viral infection other causes hepatic cirrhosis. majority patients have underlying dysfunction, which complicates patient management search for safe effective therapies. Clinical Trials Planning Meeting (CTPM) was convened by National Cancer Institute's Gastrointestinal Steering Committee...
A national conference was held to better characterize the long-term outcomes of liver transplantation (LT) for patients with hepatocellular carcinoma (HCC) and assess whether it is justified continue policy assigning increased priority candidates early-stage HCC on transplant waiting list in United States. The objectives were address specific issues as they relate allocation, develop a standardized pathology report form assessment explanted liver, more imaging criteria designed qualify LT...
A major obstacle for orthotopic liver transplantation (OLT) as treatment hepatocellular carcinoma (HCC) is tumor growth resulting in dropout from the waiting list OLT. There a paucity of data on survival according to intention-to-treat analysis and rate OLT among patients with HCC. To further evaluate these issues, we analyzed outcome 46 consecutive HCC listed between January 1998 2001. Exclusion criteria were size greater than 5 cm one three lesions or four any size. Twenty-one underwent 11...
Several factors are associated with increased hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT), but no reliable risk score has been established to determine the individual for HCC recurrence.We aimed develop and validate a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) patients meeting Milan criteria by imaging.Predictors were tested in development cohort 721 who underwent LT between 2002 2012 at 3 academic transplant centers (University...
The presence of an intrahepatic cholangiocarcinoma (iCCA) in a cirrhotic liver is contraindication for transplantation most centers worldwide. Recent investigations have shown that “very early” iCCA (single tumors ≤2 cm) may acceptable results after transplantation. This study further evaluates this finding larger international multicenter cohort. group was composed those patients who were transplanted hepatocellular carcinoma or decompensated cirrhosis and found to at explant pathology....
Serum alpha-fetoprotein (AFP) has been increasingly recognized as a marker for poor prognosis after liver transplantation (LT) hepatocellular carcinoma (HCC). Many published reports, however, have included large proportion of patients with HCC beyond the Milan criteria, and effects incorporating AFP an exclusion criterion LT remain unclear. We studied 211 consecutive undergoing within criteria according to imaging under Model End-Stage Liver Disease organ allocation system between June 2002...
<h3>Importance</h3> National guidelines on transplant selection have adopted successful downstaging to within Milan criteria (MC) as a viable option for the treatment of hepatocellular carcinoma (HCC) before liver (LT). Recurrence HCC after LT carries poor prognosis, and modalities remain challenging. <h3>Objective</h3> To establish 10-year outcomes patients with in large, multicenter US study based individual data; provide robust data long-term role downstaging; evaluate association...
In patients with hepatocellular carcinoma (HCC) exceeding conventional (T2) criteria for orthotopic liver transplantation (OLT), the feasibility and outcome following loco-regional therapy intended tumor downstaging to meet T2 OLT are unknown. this first prospective study on of HCC prior OLT, eligibility enrollment into a protocol included 1 lesion >5 cm ≤8 cm, 2 or 3 lesions at least >3 but ≤5 total diameter 4 5 nodules all ≤3 cm. Patients were eligible living-donor (LDLT) if tumors...
Uncontrolled studies have suggested a beneficial effect of lamivudine in patients with decompensated cirrhosis caused by replicating hepatitis B virus (HBV). We analyzed the outcome treatment 23 consecutive severely HBV–cirrhosis defined as Child–Pugh–Turcotte (CPT) score ≥10, and compared historical untreated control group matched for age, gender, baseline CPT score. Significant clinical response, decrease ≥3 points, was observed 14 (60.9%) treated versus none controls ( P < .0001). The...
Since our interim report of the intention-to-treat outcome orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), we have performed a follow-up analysis an expanded cohort 70 patients to further assess whether observed pattern and predictors dropout are consistent with rationale behind current HCC-adjusted Model End Stage Liver Disease (MELD) organ allocation scheme. All except one patient had pretransplantation staging meeting proposed criteria-a single lesion < or =6.5...
Mixed hepatocellular cholangiocarcinoma (HCC-CC) and intrahepatic (I-CC) are increasingly being reported in patients with cirrhosis. The aims of this study were (1) to evaluate the incidence, imaging features, posttransplant outcomes for who underwent transplantation carcinoma (HCC) found have HCC-CC or I-CC explant (2) compare these those controls HCC matched (1:3) by tumor size number nodules explant. In specimens 10 302 (3.3%) liver (LT) HCC, mixed was identified. There 4 additional...
This opinion piece explores an "ablate and wait" strategy for improving the 5-year recurrence-free outcome of liver transplantation in patients with hepatocellular carcinoma. The Milan criteria delimit by tumor size number a population who have good survival after transplantation. University California San Francisco downstaging experience has shown that burden outside undergo ablation period waiting outcomes rival those within because biology is allowed to become apparent radiological...
It has been shown that patients with hepatocellular carcinoma (HCC) meeting the United Network for Organ Sharing T2 (Milan) criteria have an advantage in comparison without HCC under current organ allocation system liver transplantation (LT). We hypothesized within group, there is a subgroup low risk of wait-list dropout should not receive same listing priority. This study evaluated 398 consecutive listed LT Model End-Stage Liver Disease exception from March 2005 to January 2011 at our...
United Network for Organ Sharing (UNOS) recently implemented a national policy granting priority listing liver transplantation (LT) in patients who achieved down-staging of hepatocellular carcinoma (HCC) to Milan criteria. We aimed evaluate the experience on by comparing two groups with (1) tumor burden meeting UNOS (UNOS-DS) inclusion criteria and (2) "all-comers" (AC-DS) initial beyond UNOS-DS versus always within Milan.